Volume 11 Issue 3
May  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(3): 344-349
Li Han, Jia Yanan, He Qiang, et al. Progress of immunosuppressant management, infection prevention and treatment after liver transplantation in severe liver disease[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 344-349. doi: 10.3969/j.issn.1674-7445.2020.03.004
Citation: Li Han, Jia Yanan, He Qiang, et al. Progress of immunosuppressant management, infection prevention and treatment after liver transplantation in severe liver disease[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 344-349. doi: 10.3969/j.issn.1674-7445.2020.03.004
shu

Progress of immunosuppressant management, infection prevention and treatment after liver transplantation in severe liver disease

doi: 10.3969/j.issn.1674-7445.2020.03.004

  • Department of Hepatobiliary-pancreatic-splenic Surgery, Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China

More Information
  • Corresponding author: Li Xianliang,Email:lixianliangbjcy@126.com
  • Received Date: 2020-02-07
    Available Online: 2021-01-19
  • Publish Date: 2020-05-15
    Abstract
  • Liver transplantation is an effective treatment of severe liver disease. However, the pathophysiological changes of patients with severe liver disease are complicated, which significantly increase the difficulty of perioperative management of liver transplantation. Therefore, it is of great significance to strengthen postoperative management of the recipients with severe liver disease after liver transplantation. In this article, the pathophysiological characteristics of severe liver disease, the selection of immunosuppressant after liver transplantation, and the prevention and treatment of infection after liver transplantation in patients with severe liver disease were summarized.

     

    • FullText(HTML)
  • loading
    • References(46)
  • [1]
    RANA A, ACKAH RL, WEBB GJ, et al. No gains in long-term survival after liver transplantation over the past three decades[J]. Ann Surg, 2019, 269(1):20-27. DOI: 10.1097/SLA.0000000000002650.
    [2]
    OLIVO R, GUARRERA JV, PYRSOPOULOS NT. Liver transplantation for acute liver failure[J]. Clin Liver Dis, 2018, 22(2):409-417. DOI: 10.1016/j.cld.2018.01.014.
    [3]
    GERMANI G, THEOCHARIDOU E, ADAM R, et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database[J]. J Hepatol, 2012, 57(2):288-296. DOI: 10.1016/j.jhep. 2012.03.017.
    [4]
    BERNAL W, JALAN R, QUAGLIA A, et al. Acute-onchronic liver failure[J]. Lancet, 2015, 386(10003):1576- 1587. DOI: 10.1016/S0140-6736(15)00309-8.
    [5]
    BERNAL W, WENDON J. Acute liver failure[J]. N Engl J Med, 2013, 369(26):2525-2534. DOI: 10.1056/NEJMra1208937.
    [6]
    European Association for the Study of the Liver, Clinical Practice Guidelines Panel, WENDON J, et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J]. J Hepatol, 2017, 66(5):1047- 1081. DOI: 10.1016/j.jhep.2016.12.003.
    [7]
    STRAVITZ RT, LEE WM. Acute liver failure[J]. Lancet, 2019, 394(10201):869-881. DOI: 10.1016/S0140-6736(19) 31894-X.
    [8]
    UMGELTER A, LANGE K, KORNBERG A, et al. Orthotopic liver transplantation in critically ill cirrhotic patients with multi-organ failure: a single-center experience[J]. Transplant Proc, 2011, 43(10):3762-3768. DOI: 10.1016/j.transproceed.2011.08.110.
    [9]
    HWANG W, LEE J. Pathophysiologic implications of cytokines secretion during liver transplantation surgery[J]. Int J Med Sci, 2018, 15(14):1737-1745. DOI: 10.7150/ijms.28382.
    [10]
    MARUDANAYAGAM R, SHANMUGAM V, SANDHU B, et al. Liver retransplantation in adults: a single-centre, 25-year experience[J]. HPB (Oxford), 2010, 12(3):217- 224. DOI: 10.1111/j.1477-2574.2010.00162.x.
    [11]
    UMBRO I, TINTI F, SCALERA I, et al. Acute kidney injury and post-reperfusion syndrome in liver transplantation[J]. World J Gastroenterol, 2016, 22(42): 9314-9323. doi: 10.3748/wjg.v22.i42.9314
    [12]
    SOOD S, TESTRO AG. Immune monitoring post liver transplant[J]. World J Transplant, 2014, 4(1):30-39. DOI: 10.5500/wjt.v4.i1.30.
    [13]
    LUO Y, JI WB, DUAN WD, et al. Delayed introduction of immunosuppressive regimens in critically ill patients after liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(5):487-492. DOI: 10.1016/S1499- 3872(17)60050-X.
    [14]
    LING X, XIONG J, LIANG W, et al. Can immune cell function assay identify patients at risk of infection or rejection? a Meta-analysis[J]. Transplantation, 2012, 93(7):737-743. DOI: 10.1097/TP.0b013e3182466248.
    [15]
    CHARLTON M, LEVITSKY J, AQEL B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients[J]. Transplantation, 2018, 102(5):727-743. DOI: 10.1097/TP.0000000000002147.
    [16]
    NEUBERGER JM, MAMELOK RD, NEUHAUS P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study[J]. Am J Transplant, 2009, 9(2):327-336. DOI: 10.1111/j.1600-6143.2008.02493.x.
    [17]
    TRUNEČKA P, KLEMPNAUER J, BECHSTEIN WO, et al. Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens-the DIAMOND study[J]. Am J Transplant, 2015, 15(7):1843-1854. DOI: 10.1111/ajt.13182.
    [18]
    LUÉ A, MARTINEZ E, NAVARRO M, et al. Donor age predicts calcineurin inhibitor induced neurotoxicity after liver transplantation[J]. Transplantation, 2019, 103(8):e211-e215. DOI: 10.1097/TP.0000000000002750.
    [19]
    刘焕业, 寇建涛, 马军, 等.肝移植治疗肝昏迷的围手术期管理经验探讨[J].器官移植, 2019, 10(3):323-327. DOI: 10.3969/j.issn.1674-7445.2019.03.017.

    LIU HY, KOU JT, MA J, et al. Experience in perioperative management of liver transplantation in hepatic coma patients[J]. Organ Transplant, 2019, 10(3):323-327. DOI: 10.3969/j.issn.1674-7445.2019.03.017.
    [20]
    ASRANI SK, WIESNER RH, TROTTER JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial[J]. Am J Transplant, 2014, 14(2):356-366. DOI: 10.1111/ajt.12543.
    [21]
    张冬华, 陈榕, 王轩, 等.肝移植术后应用巴利昔单克隆抗体诱导的无糖皮质类固醇激素免疫抑制治疗方案的临床疗效[J].中华消化外科杂志, 2018, 17(10):997- 1001. DOI: 10.3760/cma.j.issn.1673-9752.2018.10.006.

    ZHANG DH, CHEN R, WANG X, et al. Clinical efficacy of basiliximab-induced glucose-free corticosteroid immunosuppressive regimen after liver transplantation[J]. Chin J Digest Surg, 2018, 17(10):997- 1001. DOI: 10.3760/cma.j.issn.1673-9752.2018.10.006.
    [22]
    SEGEV DL, SOZIO SM, SHIN EJ, et al. Steroid avoidance in liver transplantation: Meta-analysis and Meta-regression of randomized trials[J]. Liver Transpl, 2008, 14(4):512-525. DOI: 10.1002/lt.21396.
    [23]
    FAIRFIELD C, PENNINGA L, POWELL J, et al. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients[J]. Cochrane Database Syst Rev, 2018, 4:CD007606. DOI: 10.1002/14651858.CD007606.pub4.
    [24]
    BERTACCO A, BARBIERI S, GUASTALLA G, et al. Risk factors for early mortality in liver transplant patients[J]. Transplant Proc, 2019, 51(1):179-183. DOI: 10.1016/j.transproceed.2018.06.025.
    [25]
    ABAD CL, LAHR BD, RAZONABLE RR. Epidemiology and risk factors for infection after living donor liver transplantation[J]. Liver Transpl, 2017, 23(4):465-477. DOI: 10.1002/lt.24739.
    [26]
    MOON DB, LEE SG. Liver transplantation[J]. Gut Liver, 2009, 3(3):145-165. DOI: 10.5009/gnl.2009.3.3.145.
    [27]
    吴金道, 母小新, 韩国勇, 等.2012-2015年1380株肝移植术后感染病原菌的分布及耐药性分析[J].现代药物与临床, 2015, 30(12):1546-1549. DOI:10.7501/j.issn. 1674-5515.2015.12.027.

    WU JD, MU XX, HAN GY, et al. Analysis on distribution and drug resistance of 1380 strains of pathogens infected after liver transplantation from 2012 to 2015[J]. Mod Drug Clin, 2015, 30(12):1546-1549. DOI:10.7501/j.issn. 1674-5515.2015.12.027.
    [28]
    李先亮, 吕少诚, 郎韧, 等.同种异体肝移植术后感染的常见病原菌分析[J].中华肝胆外科杂志, 2017, 23(3):205- 206. DOI:10.3760/cma.j.issn.1007-8118.2017.03.018.

    LI XL, LYU SC, LANG R, et al. Analysis of common pathogenic bacteria after liver allograft transplantation[J]. Chin J Hepatobil Surg, 2017, 23(3):205-206. DOI: 10.3760/cma.j.issn.1007-8118.2017.03.018.cma.j.issn.1007-8118.2017.03.018.
    [29]
    张达利, 高银杰, 冯丹妮, 等.肝移植术后卡氏肺孢子菌肺炎1例报告[J].临床肝胆病杂志, 2019, 35(2):384- 385. DOI: 10.3969/j.issn.1001-5256.2019.02.030.

    ZHANG DL, GAO YJ, FENG DN, et al. A case of pneumocystis carini pneumonia after liver transplantation[J]. J Clin Hepatol, 2019, 35(2):384-385. DOI:10.3969/j.issn.1001-5256. 2019.02.030.
    [30]
    AYVAZOGLU SOY EH, AKDUR A, YILDIRIM S, et al. Early postoperative infections after liver transplant[J]. Exp Clin Transplant, 2018, 16 (Suppl 1):145-148. DOI: 10.6002/ect.TOND-TDTD2017.P36.
    [31]
    KIM SI. Bacterial infection after liver transplantation[J]. World J Gastroenterol, 2014, 20(20):6211-6220. DOI: 10.3748/wjg.v20.i20.6211.
    [32]
    SHI SH, KONG HS, JIA CK, et al. Coagulase-negative staphylococcus and enterococcus as predominant pathogens in liver transplant recipients with Grampositive coccal bacteremia[J]. Chin Med J (Engl), 2010, 123(15):1983-1988. https://www.cabdirect.org/cabdirect/abstract/20113029806
    [33]
    BODRO M, SABÉ N, TUBAU F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients[J]. Transplantation, 2013, 96(9):843-849. DOI: 10.1097/TP.0b013e3182a049fd.
    [34]
    CERVERA C, VAN DELDEN C, GAVALDÀ J, et al. Multidrug-resistant bacteria in solid organ transplant recipients[J]. Clin Microbiol Infect, 2014, 20(Suppl 7): 49-73. DOI: 10.1111/1469-0691.12687.
    [35]
    ZICKER M, COLOMBO AL, FERRAZ-NETO BH, et al. Epidemiology of fungal infections in liver transplant recipients: a six-year study of a large Brazilian liver transplantation centre[J]. Mem Inst Oswaldo Cruz, 2011, 106(3):339-345. doi: 10.1590/S0074-02762011000300014
    [36]
    SALIBA F, DELVART V, ICHAÏ P, et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era[J]. Clin Transplant, 2013, 27(4):E454-E461. DOI: 10.1111/ctr.12129.
    [37]
    BARCHIESI F, MAZZOCATO S, MAZZANTI S, et al. Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases[J]. Liver Transpl, 2015, 21(2):204-212. DOI: 10.1002/lt.24032.
    [38]
    HOGEN R, DHANIREDDY KK. Invasive fungal infections following liver transplantation[J]. Curr Opin Organ Transplant, 2017, 22(4):356-363. DOI: 10.1097/MOT.0000000000000431.
    [39]
    中华医学会器官移植学分会.器官移植受者侵袭性真菌病临床诊疗技术规范(2019版)[J].器官移植, 2019, 10 (3):227-236. DOI: 10.3969/j.issn.1674-7445.2019.03.002.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specification for clinical diagnosis and treatment for invasive fungal disease in organ transplant recipients (2019 edition)[J]. Organ Transplant, 2019, 10(3):227-236. DOI:10.3969/j.issn. 1674-7445.2019.03.002.
    [40]
    EKENBERG C, DA CUNHA-BANG C, LODDING IP, et al. Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation[J]. Transpl Infect Dis, 2020:e13252. DOI: 10.1111/tid.13252.
    [41]
    NAM H, NILLES KM, LEVITSKY J, et al. Donorderived viral infections in liver transplantation[J]. Transplantation, 2018, 102(11):1824-1836. DOI: 10.1097/TP.0000000000002326.
    [42]
    中华医学会器官移植学分会.器官移植受者巨细胞病毒感染临床诊疗规范(2019版)[J].器官移植, 2019, 10(2): 142-148. DOI:10.3969/j.issn.1674-7445.2019.02.005.

    Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for cytomegalovirus infection on recipients with organ transplantation in China (2019 edition)[J]. Organ Transplant, 2019, 10(2):142-148. DOI:10.3969/j.issn.1674-7445.2019.02.005.
    [43]
    中华医学会器官移植学分会.器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版)[J].器官移植, 2019, 10(2):149-157.DOI: 10.3969/j.issn.1674-7445.2019.02.006.

    Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for EB virus infection and posttransplant lymphoproliferative disease on recipients with organ transplantation in China (2019 edition) [J]. Organ Transplant, 2019, 10(2):149-157. DOI: 10.3969/j.issn.1674-7445.2019.02.006.
    [44]
    ALLEN UD, PREIKSAITIS JK, AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation[J]. Am J Transplant, 2013, 13 (Suppl 4):107-120. DOI: 10.1111/ajt.12104.
    [45]
    MUMTAZ K, FAISAL N, MARQUEZ M, et al. Posttransplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome from a singlecentre experience with > 1000 liver transplantations[J]. Can J Gastroenterol Hepatol, 2015, 29(8):417-422. doi: 10.1155/2015/517359
    [46]
    ANGARITA SAK, RUSSELL TA, KALDAS FM. Pneumonia after liver transplantation[J]. Curr Opin Organ Transplant, 2017, 22(4):328-335. DOI: 10.1097/MOT.0000000000000427.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (177) PDF downloads(42) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return